“Vista’s View – A Weekly FREE Market Update 12-8-18″…Now Available!

Vista Partners has published “Vista’s View – A Weekly Market Update Newsletter 12-8-18!”  

Each weekly newsletter is written by Vista Partners’ Managing Director, John Heerdink.   Vista’s View includes an exclusive view on the stock market for the week, a “Stocks To Watch” section, featured stories that span from the Dow 30, select emerging growth companies, investing basics & exciting videos from Vista’s Coverage Universe and beyond.

Vista Covers all Dow 30 components, International Companies, Select Emerging Growth Companies & more on the website daily.

 Download the latest Exclusive FREE Newsletter at the Vista Partners’ Newsletters Page Now.  It’s FREE!!!

Stay Informed! Stay Competitive!  Receive our FREE email updates by signing up today in just  few seconds!

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




“Spinners” – Vista Partners Daily Market Recap 12/6/2018

We were hit with a rough morning of trading that seemed to be a reaction to the overnight arresting of the Chinese Company’s (Huawei) CFO Meng Wanzhou by Canadian authorities (also facing extradition to the US), which in turn lit fears around the trade wars and sent the markets crashing. However, some news from the Fed today helped to buoy the markets into the close.

At the end of the day, the S&P 500 dropped .15% as of market close, as the energy sector lead declines. The Dow was down only .32% after sliding quickly as many as 784.85 points earlier in the day. The Nasdaq jumped .42%, or 29.83 points as it moved into to positive territory at the close. All in it was another day of yo-yo that surely kept is all spinning.

Components of the Dow were also mixed, with Boeing (BA) leading the losers with a drop of 3.09%. JP Morgan (JPM) also had a rough day with losses of 1.90%. On the other side of the spectrum, Cisco (CSCO) ended the day up 2.20%.

Outside the Dow, Atossa Genetics (ATOS) was down 2.99% as the session closed.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Sign Up to receive FREE email updates here!

Stocks pare losses, Nasdaq closes in the green

Stocks pared losses after enduring a rollercoaster session ignited after the arrest of a Chinese telecommunications company executive muddled prospects of a U.S.-China trade resolution…

finance.yahoo.com

Read Full Article



A Growing List of Inspirational Quotes For Success!

We believe it is necessary to continue to inspire all to be their personal best in life and in investing. We also believe that keeping inspired and learning from others is an essential element to building long-term financial and emotional wealth.

With this in mind, we commit to grabbing ideas and thoughts from those that are successful in life and from investors who have conquered the markets and would encourage you to do so as well.

Here is a list of inspiring quotes that we will continue to add to over time. So please enjoy them today and come back regularly to continue to find inspiration as we add to this list.

  1. “I will tell you how to become rich. Close the doors. Be fearful when others are greedy. Be greedy when others are fearful.” – Warren Buffett
  2. “Bottoms in the investment world don’t end with four-year lows; they end with 10- or 15-year lows.” – Jim Rogers
  3. “The stock market is filled with individuals who know the price of everything, but the value of nothing.” – Phillip Fisher
  4. “The individual investor should act consistently as an investor and not as a speculator.” – Ben Graham
  5. “Financial peace isn’t the acquisition of stuff. It’s learning to live on less than you make, so you can give money back and have money to invest. You can’t win until you do this.” – Dave Ramsey
  6. “Invest in yourself, you can afford it, trust me.”- Rashon Carraway
  7. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell.” –  Jonathan Sacks
  8. “Formal education will make you a living; self-education will make you a fortune.” – Jim Rohn
  9.  “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  10. “You will come to know that what appears today to be a sacrifice will prove to be the greatest investment that you will ever make.” – Gordon B. Hinkley
  11. “In the short run, the market is a voting machine but in the long run, it is a weighing machine.”― Benjamin Graham
  12. “In the short run, the market is a voting machine but in the long run, it is a weighing machine.” ― Benjamin Graham 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Sign Up to receive FREE email updates here!




Cybersecurity Firm Finjan (FNJN) Files Complaint Against Qualys (QLYS) for Patent Infringement!

Established over 20 years ago, Palo Alto-based, Finjan (Nasdaq: FNJN) is a globally recognized leader in cybersecurity. Finjan’s inventions are embedded within a strong portfolio of patents focusing on software and hardware technologies capable of proactively detecting previously unknown and emerging threats on a real-time, behavior-based basis. Finjan continues to grow through investments in innovation, strategic acquisitions, and partnerships promoting economic advancement and job creation.

Today, Finjan announced that — after three years of “good faith efforts” to resolve a patent dispute with Qualys, Inc. ( “Qualys”) (NasdaqGM: QLYS) — its subsidiary Finjan, Inc. (“Finjan”) has filed a patent infringement lawsuit against Qualys, a Delaware corporation with headquarters in Foster City, California, in the U.S. District Court for the Northern District of California.

Finjan filed the Complaint (Case No. 3:18-cv-07229), on November 29, 2018, and alleges that Qualys’ products and services infringed and are continuing to infringe at least seven of Finjan’s U.S. patents. Specifically, Finjan asserts that Qualys’ Malware Detection Systems (MDS), Web Application Firewall (WAF), Web Application Scanner (WAS), and Vulnerability (VM) solutions, including Qualys Cloud Platform products, infringe U.S. Patent Nos. 6,154,844; 6,965,968; 7,418,731; 7,975,305; 8,141,154; 8,225,408; and 8,677,494 (collectively “the Asserted Patents”). Finjan is seeking, among other things, a jury trial, past damages not less than a reasonable royalty, enhanced damages for willful, wanton and deliberate infringement, and reasonable attorneys’ fees and costs for infringement of each of the Asserted Patents. Additionally, Finjan is seeking preliminary and permanent injunctive relief against Qualys and those in privity with them, from infringing and inducing the infringement of the ‘968, ‘731, ‘305, ‘154, and ‘408 Patents.

Finjan has pending infringement lawsuits and appeals against Palo Alto Networks (PANW); ESET and its affiliates; Cisco Systems, Inc. (CSCO); SonicWall, Inc.; Bitdefender and its affiliates; Juniper Networks; Zscaler, Inc.; Check Point (CHKP) and its affiliates; Rapid7, Inc. and Fortinet, Inc. (FTNT) relating to, collectively, more than 20 patents in the Finjan portfolio. The court dockets for the foregoing cases are publicly available on the Public Access to Court Electronic Records (PACER) website, www.pacer.gov, which is operated by the Administrative Office of the U.S. Courts.

Finjan won a significant settlement against Symantec (SYMC) earlier in 2018 where one of SYMC’s units have agreed to pay $65 million with a possibility of up to $45 million more.

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

 

 

Stay Informed! Stay Competitive! Sign Up to receive FREE email updates here!

 

 

 

Finjan Files a Complaint Against Qualys for Patent Infringement in the Northern District of California

EAST PALO ALTO, Calif., Dec. 03, 2018 — Finjan Holdings, Inc. (NASDAQ: FNJN), a cybersecurity company, today announced that — after three years of good faith efforts to…

finance.yahoo.com

Read Full Article



“Free Falling” – Vista Partners Daily Market Recap 12/4/2018

After a strong showing yesterday, the market was in a free fall on Tuesday as stocks went crashing. The S&P 500 shed 3.24% during today’s session while the Nasdaq plummeted 3.80%. The Dow plunged 3.10% as the market closed.

Individual components of the Dow were down across the board, with every single company ending the day in the red. Caterpillar (CAT) led declines with a loss of 6.93%. Other companies seeing heavy losses include Boeing (BA), with a drop of 4.85%, and Intel (INTC), which sank 4.75%.

Outside the Dow, Atossa Genetics (ATOS) didn’t fare much better. It dropped 2.90% during today’s session after impressive gains yesterday.

On the other side of the coin a bet, trade on investment in the VelocityShares Daily 2x VIX ST ETN (TVIX), a “bet against the broad markets,” paid off handsomely today as it closed at $44.47 up +25.13% on the day! Thank you triggered algorythmic trades!

Two major factors are being blamed for today’s sudden downturn. The first was yesterday’s inversion of the 3-year and 5-year notes, a warning sign pointing to a possible recession. This was the first inversion since 2007 and served to spook already wary investors.

The second factor was the contradictions from the White House on the exact nature of the trade deal with China that President Trump had touted this weekend. These differing reports led many to believe that the deal may not be as solid as the president had made it seem. Basically fear crept back into the markets prior to tomorrow’s closure of the markets in honor of George H. W. Bush.

Jim Tierney, with Alliance Bernstein sees a very bleak future as quite possible if Trump isn’t able to assure investor’s that the trade tensions are under control. “If we have a trade problem, I think that risks bringing a number of developing economies to the brink of recession. It also puts a huge tax of U.S. consumers, and the combination of those two means a pretty meaningful global slowdown, which would indicate that right now the yield curve is correct in terms of where we’re going,” Tierney noted.

One might also point to the selloff being due in part to the unsettling nature of a Wednesday market closing with all outstanding aforementioned issues directly related to the US unresolved and the worldwide issue of the Brexit situation. The fear surrounding the market was too much for many to handle…understandably so.

Tomorrow will provide a break from today’s turmoil as the market is closing in honor of deceased President George H.W. Bush’s funeral. Rest in peace President Bush.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Sign Up to receive FREE email updates here!

Stocks nosedive, Dow sheds nearly 800 points

Stocks tanked Tuesday as a slew of concerns over trade tensions and an inversion in part of the U.S. yield curve spooked investors…

finance.yahoo.com

Read Full Article



Markets React Well to Atossa Genetics (ATOS) Announcing FDA Approval For “Expanded Access”

Atossa Genetics Inc., (NasdaqCM; ATOS) is a Seattle-based clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. ATOS announced on Monday that the FDA has approved an “expanded access” of Atossa’s proprietary oral Endoxifen in the preoperative setting in a U.S. patient awaiting surgery for breast cancer. Under the FDA Expanded Access IND program, the use of Atossa’s proprietary Endoxifen is restricted to this patient only.

The markets reacted positively to this news on Monday as ATOS shot up over 50% and hit a high of $1.85 while trading north of 16.8 million shares or approximately $28-30 million dollars of trading before closing at $1.38.

Note that Atossa is currently conducting a Phase 2 study of its oral Endoxifen in Australia in the “window of opportunity” between diagnosis of breast cancer and surgery.  Steven C. Quay, Ph.D., MD, President and CEO stated. “Once a patient is diagnosed with breast cancer, there is a window of time, typically a few weeks, before surgery is performed. Our goal with this study is to show that our proprietary oral Endoxifen can modify the cancer activity in ER+ breast cancer during this ‘window of opportunity.’ Because our Phase 1 study indicated that our oral Endoxifen reaches therapeutic levels within 8 hours and therapeutic steady-state levels in only seven days, we are optimistic we can achieve a valuable treatment effect.”

The Pilot Phase of the study will initially enroll up to eight newly-diagnosed patients with ER+ and HER2 negative (HER2-) stage 1 or 2 invasive breast cancer, requiring mastectomy or lumpectomy. Patients will receive Atossa’s proprietary oral Endoxifen for at least 21 days from the time of diagnosis up to the day of surgery. Provided tumor activity reduction is demonstrated in at least two patients, an additional 17 patients will be enrolled for a total of 25. The primary endpoint is to determine if the administration of oral Endoxifen reduces the tumor activity as measured by Ki-67, which is a marker of cellular proliferation. The secondary endpoints are safety and tolerability and assessment of the study drug on expression levels of both estrogen and progesterone receptors. The impact on additional markers of cellular activity will also be explored. The Phase 2 study is being conducted on behalf of Atossa by CPR Pharma Services Pty Ltd., Thebarton, SA, Australia. CPR Pharma recently completed the successful Phase 1 study of Atossa’s oral and topical Endoxifen in women.

Steven C. Quay, Ph.D., MD, President and CEO commented further, “A physician recently contacted Atossa and requested our proprietary oral Endoxifen for a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient awaiting surgery. In this setting, the recommended preoperative endocrine systemic therapy is typically an aromatase inhibitor and a drug for ovarian suppression. The patient’s physician was reluctant to use this preoperative therapy as it typically induces menopause and can have other potentially serious side effects. We worked with the physician to apply to the FDA to provide “expanded access” (formerly known as compassionate use) to this patient under an Investigational New Drug (IND) application. We are very pleased to report that the FDA approved this single-patient study, and the patient is currently receiving our proprietary oral Endoxifen preoperatively. This is the same clinical setting as our Phase 2 ‘window of opportunity’ study of preoperative systemic oral Endoxifen in breast cancer patients which is open for enrollment in Australia.”

Note that expanded access, sometimes called “compassionate use, is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. Expanded access may be appropriate when all the following apply: patient has a serious disease or condition, or whose life is immediately threatened by their disease or condition; there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; patient enrollment in a clinical trial is not possible; potential patient benefit justifies the potential risks of treatment; providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication. Investigational drugs, biologics or medical devices have not yet been approved or cleared by FDA and FDA has not found these products to be safe and effective for their specific use. Furthermore, the investigational medical product may, or may not, be effective in the treatment of the condition, and use of the product may cause unexpected serious side effects. For more information, see the FDA website: FDA Expanded Use Website

If you found this story interesting you should consider following Atossa Genetics (Nasdaq: ATOS)  please see Atossa the dedicated coverage page at Vista Partners to learn more.

Atossa Genetics Announces FDA Approval of Endoxifen for “Expanded Access” as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient

Steven C. Quay, Ph.D., MD, President and CEO commented, “A physician recently contacted Atossa and requested our proprietary oral Endoxifen for a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient awaiting surgery. In this setting, the recommended preoperative endocrine systemic..

finance.yahoo.com

Read Full Article



First Choice Bancorp (FCBP) Adopts Stock Repurchase Program – Possibly Up To ~10% Of Outstanding Shares

First Choice Bancorp is the registered bank holding company for First Choice Bank. First Choice Bank, headquartered in Cerritos, California is a community-focused financial institution, serving diverse consumers and commercial clients and specializing in loans to small businesses, private banking clients, commercial and industrial (C&I) loans, and commercial real estate loans with a niche in providing finance for the hospitality industry. First Choice Bank is a Preferred Small Business Administration (SBA) Lender. Founded in 2005, First Choice Bank has quickly become a leading provider of financial services that enable their customers to grow, maintain strength, and achieve their business objectives.  First Choice Bancorp stock is traded on the Nasdaq Capital Market under the ticker symbol “FCBP”. First Choice Bank’s website is www.FirstChoiceBankCA.com.

FCBP announced today that its Board of Directors has adopted a stock repurchase program. Under the repurchase program, the Company may repurchase up to 1.2 million shares of its common stock, or approximately 10% of its outstanding shares. The repurchase program permits shares to be repurchased in open market or private transactions, through block trades, and pursuant to any trading plan that may be adopted in accordance with Rules 10b5-1 and 10b-18 of the Securities and Exchange Commission. Repurchases will be made at management’s discretion at prices management considers to be attractive and in the best interests of both the Company and its shareholders, subject to the availability of stock, general market conditions, the trading price of the stock, alternative uses for capital, and the Company’s financial performance. Open market purchases will be conducted in accordance with the limitations set forth in Rule 10b-18 of the Securities and Exchange Commission and other applicable requirements. The repurchase program may be suspended, terminated or modified at any time for any reason, including market conditions, the cost of repurchasing shares, the availability of alternative investment opportunities, liquidity, and other factors deemed appropriate. These factors may also affect the timing and amount of share repurchases. The repurchase program does not obligate the Company to purchase any particular number of shares.

To follow FCBP’s progress please visit the Vista Partners’ FCBP dedicated page which is updated daily.

 

First Choice Bancorp Announces Stock Repurchase Program

CERRITOS, CALIFORNIA, Dec. 03, 2018 (GLOBE NEWSWIRE) — (Nasdaq Capital Markets: FCBP) – First Choice Bancorp, the holding company for First Choice Bank (the “Bank,” collectively, “First Choice”) announced today that its Board of Directors has adopted a stock repurchase program. Under the repurchase..

finance.yahoo.com

Read Full Article



In Honor of President George H.W. Bush, Markets to Be Closed Wednesday, Dec. 5th

Several US markets will be closed on Wednesday, December, 5th 2019 as the country observes a national day of mourning in honor of former President George H.W. Bush who died on Friday.

The CME Group’s equities markets, Nasdaq’s US equities and options markets, and the NYSE will all close on Wednesday in addition to having a moment of silence for the deceased president on Monday.

This marks the first time in just over a decade that US financial markets have closed to honor the death of a president, with the last instance coming in 2007 after the death of President Gerald Ford.

The funeral for President Bush, the 41st president, will be on Wednesday and President Trump has declared it a National Day of Mourning. According to Sarah Huckabee Sanders, the White House Press Secretary, “He and the First Lady will attend the funeral at the National Cathedral in Washington, D.C.”

George Herbert Walker Bush was born on June 12, 1924, in Milton, MA & recently past away on November 30, 2018, in Houston, TX. President Bush was an American politician who served as the 41st President of the United States from 1989 to 1993. Prior to assuming the presidency, Bush served as the 43rd Vice President of the United States from 1981 to 1989.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

U.S. Financial Markets to Shut Wednesday to Honor Bush

The New York Stock Exchange, Nasdaq Inc.’s U.S. equities and options markets and CME Group Inc.’s U.S.-based equity markets will shut, the companies said. The Securities Industry and Financial Markets Association has also recommended that fixed-income cash markets close on Wednesday, according to a..

finance.yahoo.com

Read Full Article



“Vista’s View – A Weekly FREE Market Update 12-1-18″…Now Available!

Vista Partners has published “Vista’s View – A Weekly Market Update Newsletter 12-1-18!”  Each weekly newsletter is written by Vista Partners’ Managing Director, John Heerdink.   Vista’s View includes an exclusive view on the stock market for the week, a “Stocks To Watch” section, featured stories that span from the Dow 30, select emerging growth companies, investing basics & exciting videos from Vista’s Coverage Universe and beyond.

Vista Covers all Dow 30 components, International Companies, Select Emerging Growth Companies & more on the website daily.

 Download the latest Exclusive FREE Newsletter at the Vista Partners’ Newsletters Page Now.  It’s FREE!!!

Stay Informed! Stay Competitive!  Receive our FREE emial updates by signing up today in just  few seconds!

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




Vista Partners Inspirational Quote Of The Day Via Jim Rogers

“Bottoms in the investment world don’t end with four-year lows; they end with 10- or 15-year lows.” – Jim Rogers

James Beeland Rogers Jr. is an American businessman and financial commentator based in Singapore. Rogers is the Chairman of Rogers Holdings and Beeland Interests, Inc. He was the co-founder of the Quantum Fund and Soros Fund Management. He was also the creator of the Rogers International Commodities Index.

Receive FREE email Updates from Vista Partners Today!

Founded in 2005, Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights FREE via the Vista Partners website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive.

Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors.

Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.